Gupta, Manish

Clinical pharmacology considerations for the development of immune checkpoint inhibitors

Sheng, J., Srivastava, S., Sanghavi, K., Lu, Z., Schmidt, B. J., Bello, A., & Gupta, M. (2017) · The Journal of Clinical Pharmacology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 124

QSP toolbox: computational implementation of integrated workflow components for deploying multi-scale mechanistic models.

Cheng, Y., Thalhauser, C. J., Smithline, S., Pagidala, J., Miladinov, M., Vezina, H. E., Gupta, M., Leil, T. A., & Schmidt, B. J. (2017) · The AAPS Journal

Statistical Methods in Clinical TrialsComputational Drug Discovery Methods

Cited by 54

Semimechanistic Physiologically‐Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B‐Cell Lymphomas

Li, T., Hiemstra, I. H., Chiu, C., Oliveri, R. S., Elliott, B., DeMarco, D., Salcedo, T., Egerod, F. L., Sasser, K., Ahmadi, T., et al. (2022) · Clinical Pharmacology & Therapeutics

Monoclonal and Polyclonal Antibodies ResearchLymphoma Diagnosis and Treatment

Cited by 34

Optimal Dosing Regimen for Epcoritamab, a Subcutaneous Bispecific Antibody, in Relapsed or Refractory Large B-Cell Lymphoma.

Li, T., Gibiansky, L., Parikh, A., Putnins, M., Chiu, C. W., Sacchi, M., Feng, H., Ahmadi, T., Gupta, M., & Xu, S. (2025) · Clinical Pharmacology & Therapeutics

Lymphoma Diagnosis and TreatmentMonoclonal and Polyclonal Antibodies Research

Cited by 7

Novel Semi-Mechanistic Model Leveraging Preclinical and Clinical Data to Inform the Recommended Phase 2 Dose (RP2D) Selection for Epcoritamab (DuoBody CD3xCD20)

Li, T., Hiemstra, I. H., Chiu, C., Oliveri, R. S., DeMarco, D., Salcedo, T. W., Lihme Egerod, F., & Gupta, M. (2020) · Blood

Monoclonal and Polyclonal Antibodies ResearchStatistical Methods in Clinical Trials

Cited by 4